TRDA Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
898.0K
+2.6%
875.0K
-32.6%
1.3M
-19.5%
1.6M
-17.2%
1.9M
Cost of Revenue
0
0
0
0
0
Gross Profit
898.0K
+2.6%
875.0K
-32.6%
1.3M
-19.5%
1.6M
-17.2%
1.9M
Operating Expenses
45.9M
+6.2%
43.2M
-0.8%
43.5M
-10.6%
48.7M
-0.3%
48.8M
R&D
35.4M
+7.0%
33.1M
-2.7%
34.0M
-11.5%
38.4M
+1.3%
37.9M
SG&A
10.5M
+3.6%
10.1M
+6.0%
9.6M
-7.3%
10.3M
-5.7%
10.9M
Operating Income
-44963000
-6.3%
-42303000
-0.2%
-42208000
+10.3%
-47051000
-0.4%
-46849000
EBITDA
-44122000
-6.3%
-41498000
-0.4%
-41322000
+9.8%
-45821000
-0.0%
-45815000
Net Income
-42763000
-7.7%
-39717000
-1.4%
-39164000
+11.3%
-44134000
-2.4%
-43103000
EPS (Basic)
$-1.01
-6.3%
$-0.95
-1.1%
$-0.94
+11.3%
$-1.06
-1.9%
$-1.04
EPS (Diluted)
$-1.01
-6.3%
$-0.95
-1.1%
$-0.94
+11.3%
$-1.06
-1.9%
$-1.04
Shares (Diluted)
42.2M
+0.9%
41.8M
+0.5%
41.6M
+0.4%
41.5M
+0.3%
41.3M
Entrada Therapeutics (TRDA) โ€” Financials